Barclays PLC Sells 81,343 Shares of Indivior PLC (NASDAQ:INDV)

Barclays PLC lowered its position in Indivior PLC (NASDAQ:INDVFree Report) by 18.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 365,370 shares of the company’s stock after selling 81,343 shares during the period. Barclays PLC’s holdings in Indivior were worth $8,430,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Jefferies Financial Group Inc. purchased a new stake in shares of Indivior during the second quarter valued at approximately $13,575,000. JPMorgan Chase & Co. purchased a new stake in shares of Indivior during the second quarter valued at approximately $23,101,000. Premier Fund Managers Ltd purchased a new stake in shares of Indivior during the second quarter valued at approximately $18,901,000. Boothbay Fund Management LLC purchased a new stake in shares of Indivior during the second quarter valued at approximately $21,912,000. Finally, Citigroup Inc. purchased a new stake in shares of Indivior during the second quarter valued at approximately $4,947,000. Hedge funds and other institutional investors own 36.26% of the company’s stock.

Indivior Stock Performance

NASDAQ:INDV opened at $17.39 on Thursday. The firm has a market cap of $2.40 billion, a PE ratio of -9.99 and a beta of 0.41. Indivior PLC has a fifty-two week low of $14.38 and a fifty-two week high of $26.50. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.87 and a current ratio of 0.98. The business has a 50 day moving average price of $16.06 and a 200-day moving average price of $19.22.

Indivior (NASDAQ:INDVGet Free Report) last released its quarterly earnings data on Thursday, November 9th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.04. The firm had revenue of $271.00 million during the quarter, compared to analyst estimates of $265.00 million. Indivior had a positive return on equity of 370.37% and a negative net margin of 22.57%. Equities research analysts predict that Indivior PLC will post 1.39 earnings per share for the current year.

Indivior Profile

(Free Report)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia.

Read More

Want to see what other hedge funds are holding INDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Indivior PLC (NASDAQ:INDVFree Report).

Institutional Ownership by Quarter for Indivior (NASDAQ:INDV)

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.